Delcath Systems (NASDAQ:DCTH) Announces Earnings Results

Delcath Systems (NASDAQ:DCTH) issued its earnings results on Tuesday. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19, RTT News reports. The company had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. Delcath Systems had a negative return on equity of 1,007.65% and a negative net margin of 2,308.86%. During the same period in the previous year, the firm posted ($0.86) earnings per share.

Delcath Systems Trading Down 4.5 %

Shares of Delcath Systems stock traded down $0.23 during trading on Thursday, hitting $4.86. The stock had a trading volume of 175,898 shares, compared to its average volume of 217,690. The business has a fifty day moving average of $4.34 and a two-hundred day moving average of $3.84. Delcath Systems has a fifty-two week low of $2.25 and a fifty-two week high of $7.99. The company has a current ratio of 3.30, a quick ratio of 3.11 and a debt-to-equity ratio of 0.08.

Insider Buying and Selling

In other Delcath Systems news, Director Gil Aharon bought 26,882 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were acquired at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the acquisition, the director now directly owns 1,069,710 shares of the company’s stock, valued at $3,979,321.20. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 21.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds have recently modified their holdings of DCTH. Vanguard Group Inc. raised its holdings in Delcath Systems by 19.7% during the 4th quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock worth $2,172,000 after buying an additional 85,948 shares during the period. Geode Capital Management LLC raised its holdings in shares of Delcath Systems by 85.8% during the second quarter. Geode Capital Management LLC now owns 116,536 shares of the company’s stock valued at $679,000 after acquiring an additional 53,803 shares during the period. Cibc World Market Inc. lifted its position in shares of Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after acquiring an additional 3,432 shares in the last quarter. Northern Trust Corp boosted its stake in Delcath Systems by 82.7% in the 4th quarter. Northern Trust Corp now owns 60,667 shares of the company’s stock worth $252,000 after purchasing an additional 27,458 shares during the period. Finally, BlackRock Inc. grew its position in Delcath Systems by 183.7% during the 2nd quarter. BlackRock Inc. now owns 47,180 shares of the company’s stock worth $275,000 after purchasing an additional 30,548 shares in the last quarter. 61.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DCTH has been the subject of a number of recent research reports. StockNews.com upgraded Delcath Systems to a “sell” rating in a research note on Wednesday. HC Wainwright upped their price target on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.